Anti‐CTLA4 monoclonal antibodies with vs without anti‐PD1 monoclonal antibodies
Tumour response · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies with leads to higher tumour response compared with without anti‐PD1 monoclonal antibodies (high certainty).
1 finding from 1 review
- RR 3.5 [2.07, 5.92]738 participantsHigh